Rosemurgy A S, Serafini F M
Center for Digestive Disorders, University of South Florida, Tampa, FL, USA.
Cancer Control. 2000 Sep-Oct;7(5):437-51. doi: 10.1177/107327480000700506.
The aggressiveness of pancreatic adenocarcinoma makes it a deadly disease, with its incidence rate and fatality rate almost equal. Surgery represents the only means to provide cure to patients with pancreatic cancer, though the 5-year survival is less than 10%.
We review the data on surgical and systemic therapies and provide more details on a newer biologically based medical approach.
Neoadjuvant chemotherapy protocols are confined to one or two institutions, and adjuvant chemotherapy and chemoradiation therapy protocols are far from being standardized. Chemoradiation therapy for locally advanced pancreatic cancer offers limited benefits. Protocols that include gemcitabine and 5-fluorouracil, while comparing favorably to historical controls, offer median survivals at approximately 8 months.
More effective protocols with combinations of approaches agents are needed to improve the treatment of pancreatic cancer.
胰腺腺癌的侵袭性使其成为一种致命疾病，其发病率和死亡率几乎相等。手术是为胰腺癌患者提供治愈的唯一手段，尽管5年生存率低于10%。
我们回顾了手术和全身治疗的数据，并提供了一种更新的基于生物学的医学方法的更多细节。
新辅助化疗方案仅限于一两个机构，辅助化疗和放化疗方案远未标准化。局部晚期胰腺癌的放化疗益处有限。包括吉西他滨和5-氟尿嘧啶的方案，虽然与历史对照相比效果较好，但中位生存期约为8个月。
需要更有效的联合治疗方案来改善胰腺癌的治疗。
